DDInter624 DDInter1002
Efavirenz (brand names Sustiva® and Stocrin®) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) and is used as part of highly active antiretroviral therapy (HAART) for the treatment of a human immunodeficiency virus (HIV) type 1. For HIV infection that has not previously been treated, efavirenz and lamivudine in combination with zidovudine or tenofovir is the preferred NNRTI-based regimen. Efavirenz is also used in combination with other antiretroviral agents as part of an expanded postexposure prophylaxis regimen to prevent HIV transmission for those exposed to materials associated with a high risk for HIV transmission.
Ixazomib a second generation proteasome inhibitor (PI) and the first oral PI approved by the FDA in November 2015 for multiple myeloma treatment in combination with 2 other therapies (lenalidomide and dexamethasone) for patients who have received at least 1 prior therapy. It was found to have similar efficacy to bortezomib (the first PI approved for multiple myeloma therapy) in the control of myeloma growth and prevention of bone loss. Ixazomib citrate is marketed by Takeda Pharmaceuticals under the brand name Ninlaro, which is a prodrug that becomes quickly converted to its active metabolite, ixazomib, after administration.
Efavirenz {u} (Compound) causes {v} (Side Effect) Thrombophlebitis
Thrombophlebitis {u} (Side Effect) is caused by {v} (Compound) Linezolid
Linezolid {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ixazomib
Efavirenz {u} (Compound) causes {v} (Side Effect) Thrombophlebitis
Thrombophlebitis {u} (Side Effect) is caused by {v} (Compound) Carbamazepine
Carbamazepine {u} may lead to a major life threatening interaction when taken with {v} Ixazomib
Efavirenz {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Bosentan
Bosentan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ixazomib
Efavirenz {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Clozapine
Clozapine {u} may lead to a major life threatening interaction when taken with {v} Ixazomib
Efavirenz {u} (Compound) treats {v} (Disease) acquired immunodeficiency syndrome
acquired immunodeficiency syndrome {u} (Disease) is treated by {v} (Compound) Nevirapine
Nevirapine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ixazomib
Efavirenz {u} (Compound) upregulates {v} (Gene) IKBKB
IKBKB {u} (Gene) is bound by {v} (Compound) Auranofin
Auranofin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ixazomib
Efavirenz {u} (Compound) upregulates {v} (Gene) TBX2
TBX2 {u} (Gene) is upregulated by {v} (Compound) Omacetaxine mepesuccinate
Omacetaxine mepesuccinate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ixazomib
Efavirenz {u} (Compound) is included by {v} (Pharmacologic Class) Cytochrome P450 3A4 Inhibitors
Cytochrome P450 3A4 Inhibitors {u} (Pharmacologic Class) includes {v} (Compound) Amiodarone
Amiodarone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ixazomib
Efavirenz {u} (Compound) is included by {v} (Pharmacologic Class) Cytochrome P450 2B6 Inducers
Cytochrome P450 2B6 Inducers {u} (Pharmacologic Class) includes {v} (Compound) Carbamazepine
Carbamazepine {u} may lead to a major life threatening interaction when taken with {v} Ixazomib
Efavirenz {u} (Compound) downregulates {v} (Gene) POLR2I
POLR2I {u} (Gene) is downregulated by {v} (Compound) Clozapine
Clozapine {u} may lead to a major life threatening interaction when taken with {v} Ixazomib
Efavirenz (Compound) causes Thrombophlebitis (Side Effect) and Thrombophlebitis (Side Effect) is caused by Linezolid (Compound) and Linezolid may cause a moderate interaction that could exacerbate diseases when taken with Ixazomib
Efavirenz (Compound) causes Thrombophlebitis (Side Effect) and Thrombophlebitis (Side Effect) is caused by Carbamazepine (Compound) and Carbamazepine may lead to a major life threatening interaction when taken with Ixazomib
Efavirenz (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Bosentan (Compound) and Bosentan may cause a moderate interaction that could exacerbate diseases when taken with Ixazomib
Efavirenz (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Clozapine (Compound) and Clozapine may lead to a major life threatening interaction when taken with Ixazomib
Efavirenz (Compound) treats acquired immunodeficiency syndrome (Disease) and acquired immunodeficiency syndrome (Disease) is treated by Nevirapine (Compound) and Nevirapine may cause a moderate interaction that could exacerbate diseases when taken with Ixazomib
Efavirenz (Compound) upregulates IKBKB (Gene) and IKBKB (Gene) is bound by Auranofin (Compound) and Auranofin may cause a moderate interaction that could exacerbate diseases when taken with Ixazomib
Efavirenz (Compound) upregulates TBX2 (Gene) and TBX2 (Gene) is upregulated by Omacetaxine mepesuccinate (Compound) and Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Ixazomib
Efavirenz (Compound) is included by Cytochrome P450 3A4 Inhibitors (Pharmacologic Class) and Cytochrome P450 3A4 Inhibitors (Pharmacologic Class) includes Amiodarone (Compound) and Amiodarone may cause a moderate interaction that could exacerbate diseases when taken with Ixazomib
Efavirenz (Compound) is included by Cytochrome P450 2B6 Inducers (Pharmacologic Class) and Cytochrome P450 2B6 Inducers (Pharmacologic Class) includes Carbamazepine (Compound) and Carbamazepine may lead to a major life threatening interaction when taken with Ixazomib
Efavirenz (Compound) downregulates POLR2I (Gene) and POLR2I (Gene) is downregulated by Clozapine (Compound) and Clozapine may lead to a major life threatening interaction when taken with Ixazomib